Everything below concerns receptor agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
市售注射用制剂通常要求在二至八摄氏度冷藏保存，并避免光照与冻结。部分多剂量笔在首次使用后允许在不超过三十摄氏度的环境中存放有限周数，具体期限由辅料与防腐剂体系决定。反复冻融会促进肽链聚集并改变可见颗粒计数，因此应予避免。冻干粉末在干燥、避光、低温条件下更为稳定。溶液配制后宜使用低吸附容器，以减少肽类在塑料或玻璃表面的损失。
纯度评价多采用反相高效液相色谱，流动相常加入三氟乙酸或甲酸作为离子对改性剂，检测波长设在二百一十四纳米或二百二十纳米。分子量确认依靠电喷雾电离质谱或基质辅助激光解吸电离质谱，实测值应与理论值在数 ppm 内吻合。肽图分析通过酶切后液相色谱串联质谱完成，用于核查序列与修饰位点。体积排阻色谱用于定量共价与非共价聚集体。生物基质浓度测定则采用免疫分析或液相色谱串联质谱。
The actions of estrogen are mediated by the estrogen receptor (ER), a dimeric nuclear protein that binds to DNA and controls gene expression. Like other steroid hormones, estrogen enters passively into the cell where it binds to and activates the estrogen receptor. The estrogen:ER complex binds to specific DNA sequences called a hormone response element to activate the transcription of target genes (in a study using an estrogen-dependent breast cancer cell line as model, 89 such genes were identified). Since estrogen enters all cells, its actions are dependent on the presence of the ER in the cell. The ER is expressed in specific tissues including the ovary, uterus and breast. The metabolic effects of estrogen in postmenopausal women have been linked to the genetic polymorphism of the ER. While estrogens are present in both men and women, they are usually present at significantly higher levels in biological females of reproductive age. They promote the development of female secondary sexual characteristics, such as breasts, darkening and enlargement of nipples, and thickening of the endometrium and other aspects of regulating the menstrual cycle. In males, estrogen regulates certain functions of the reproductive system important to the maturation of sperm and may be necessary for a healthy libido. Estrogens promote lung function in rodents by supporting alveoli and protect from acute kidney injury in females.
=== No development reported === AB-101 (RJ-101) – undefined mechanism of action – female sexual dysfunction [41] Apomorphine intranasal – non-selective dopamine receptor agonist, other actions – erectile dysfunction, female sexual dysfunction [42] Armodafinil ((R)-modafinil; D-modafinil; NH-02D; NH02D) – atypical dopamine reuptake inhibitor (DRI) – premature ejaculation [43] [44] Deuterated testosterone (d3-testosterone) – androgen (androgen receptor agonist) – female sexual dysfunction [45] Epelsiban (GSK557296; GSK-557296) – oxytocin receptor antagonist – premature ejaculation [46] Estradiol/testosterone topical gel (LibiGel-E/T; testosterone/estradiol topical gel) – combination of estradiol (estrogen) and testosterone (androgen) – female sexual dysfunction [47] Fibroblast growth factor 1 (FGF-1; FGF1; Acidic FGF; aFGF; Cardio Vascu-Grow; CVBT-141P; CVBT-141S; CVBT-141A; CVBT-141B; CVBT-141C; CVBT-141D; CVBT-141E; CVBT-141ED; CVBT-141F; CVBT-141G; CVBT-141H; FGF-1(141); VT-141D; VT-141ED; VT-141P; VT-141S) – fibroblast growth factor receptor (FGFR) agonist – erectile dysfunction [48] FKK-01PD (FKK-01PD; TGHW-01AP; TGHW01AP) – non-selective dopamine receptor agonist, other actions (apomorphine prodrug) – erectile dysfunction [49] GSK-958108 (GSK958108) – serotonin 5-HT1A receptor antagonist – premature ejaculation [50] HCP-1302 (HCP1302) – undefined mechanism of action – erectile dysfunction [51] Lidocaine topical gel – sodium channel blocker, local anesthetic – dyspareunia [52] PTL-2015 – undefined mechanism of action – erectile dysfunction [53] Research programme: nerve-targeted gene therapy - Periphagen (NC-3; NE-2; NE2-Endomorphin; NG-2; NG2-GAD; NN1-Neurotrophin) – various actions – erectile dysfunction [54] Research programme: sexual dysfunction therapy - Palatin Technologies (PL-6983) – melanocortin receptor modulators – erectile dysfunction, female sexual dysfunction [55] Sildenafil (KW-25084) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [56] Sildenafil orally soluble film (CURE-5003; CUREfilm Blue) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [57] Sildenafil oral spray (Duromist; NVD-401; SUD-003; SUD-004; SUDA-004; Sudamist) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [58] Tadalafil dry powder inhalation (Tadalafil Technosphere) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [59] Tadalafil orodispersible film tablet (Caliberi) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [60] Tadalafil topical (Extrinsa) – phosphodiesterase PDE5 inhibitor – female sexual dysfunction [61] Tadalafil/tamsulosin – combination of tadalafil (phosphodiesterase PDE5 inhibitor) and tamsulosin (α1-adrenergic receptor antagonist) – erectile dysfunction [62] Tunodafil (ecocarbamate; gluconocin; yonkenafil) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [63] Vilazodone (EMD-68843; SB-659746A; Viibryd) – serotonin reuptake inhibitor (SRI), serotonin 5-HT1A receptor agonist – sexual function disorders [64] Zotarolimus (ABT-578; Endeavor; Endeavor Resolute; MDT-4107 DES; Resolute DES; Resolute Integrity; Resolute Onyx; ZoMaxx) – FK-binding protein 12 (FKBP12) ligand and mechanistic target of rapamycin (mTOR) inhibitor – erectile dysfunction [65]
Several rare diseases increase susceptibility to infections from childhood onward. Primary immunodeficiency is also known as congenital immunodeficiency. Many of these disorders are hereditary and are autosomal recessive or X-linked. There are over 95 recognised primary immunodeficiency syndromes; they are generally grouped by the part of the immune system that is malfunctioning, such as lymphocytes or granulocytes. The treatment of primary immunodeficiencies depends on the nature of the defect. It may involve antibody infusions, long-term antibiotics, and, in some cases, stem cell transplantation. The characteristics of lacking and/or impaired antibody functions can be related to illnesses such as X-Linked Agammaglobulinemia and Common Variable Immune Deficiency.
Fake-fiction is a genre that deliberately presents real, unscripted events in the form of a fiction film, making them appear staged. The concept was introduced by Pierre Bismuth to describe his 2016 film Where is Rocky II?
Sources: en.wikipedia.org
=== Discontinued === Balovaptan (RG-7314, RO-5028442, RO-5285119) – vasopressin V1A receptor antagonist Blarcamesine (AE-37, ANA001, ANAVEX 2-73) – sigma σ1, muscarinic acetylcholine M1, and ionotropic glutamate NMDA receptor agonist Brilaroxazine (RP-5063, RP-5000) – dopamine D2, D3, D4 receptor partial agonist, serotonin 5-HT1A receptor agonist, serotonin 5-HT2A, 5-HT2B, 5-HT7 receptor antagonist, and atypical antipsychotic Bumetanide oral liquid (S-95008) – sodium–potassium–chloride symporter/cotransporter inhibitor and indirect GABAergic inhibitor discontinued after failed phase 3 trial Carbetocin (CYP-2001) – oxytocin receptor agonist CX-516 (1-BCP; BDP-12, SPD-420; AMPAlex) – AMPA receptor modulator EM-036 (memantine analogue) – ionotropic glutamate NMDA receptor antagonist, other actions Fasoracetam (AEVI-001, LAM-105, MDGN-001, NFC-1, NS-105) – various actions and racetam Fluoxetine rapid-dissolve (AT-001; AT001; NPL-2008; Serelsa; Zydis™ ODT fluoxetine) – serotonin reuptake inhibitor GTS-21 (DMXB-A, DMXB-A sustained release, DMXB-A-SR) – α7 nicotinic acetylcholine receptor partial agonist Ketamine intranasal (RVT-701) – ionotropic glutamate NMDA receptor antagonist Memantine (Namenda) – ionotropic glutamate NMDA receptor antagonist, other actions Oxytocin intranasal (Syntocinon Nasal Spray; TUR 001) – oxytocin receptor agonist Research programme: AMPA receptor agonists (ampakines, AMPAkines; CX compounds) - RespireRx – ionotropic glutamate AMPA receptor agonists Research programme: NMDA receptor modulators - AbbVie/Naurex (NRX-1050; NRX-1051; NRX-1059; NRX-105x; NRX-1060; NRX-2085; NRX-20xx) – ionotropic glutamate NMDA receptor modulators Risperidone extended-release (Risperisphere) – dopamine D2 and D3 receptor antagonist, serotonin 5-HT1B, 5-HT2A, 5-HT2C, and 5-HT7 receptor antagonist or inverse agonist, α1- and α2-adrenergic receptor antagonist, histamine H1 receptor inverse agonist, and atypical antipsychotic Secretin (INN-329, RG-1068; SecreFlo) – medical imaging enhancer (diagnosis) Suramin (Antrypol) – DNA-directed DNA polymerase inhibitor and intercellular signaling peptide/protein inhibitor Trichuris suis ova (CNDO-201, TSO, TSO-2500, TSO-7500) – immunomodulator Trofinetide (Daybue; G-2Me-PE; Glycyl-2-methyl-L-prolyl-L-glutamic acid; NNZ-2566; IGF-1 (1–3) analogue) – unknown / various actions
=== Mechanism of action === The primary mechanism of the bactericidal effect of Guanacastepene A is direct damage to the bacterial membrane. Mechanistic studies on Escherichia coli imp demonstrate that treatment with the active ingredient leads to a rapid and massive efflux of intracellular potassium, which is indicative of membrane perforation. The interaction with the lipid bilayer of the cell membrane is presumably due to the fact that the molecular structure, with one polar and one hydrophobic side, exhibits an amphiphilic character. Furthermore, studies on macromolecular synthesis have shown that Guanacastepene A inhibits the incorporation of radioactively labeled precursors into DNA, RNA, and proteins almost simultaneously.
A coffee bean is a seed from the Coffea plant and the source for coffee. This fruit is often referred to as a coffee cherry, but unlike the cherry, which usually contains a single pit, it most commonly contains two seeds with their flat sides together. The seeds are referred to as beans because of their appearance, though they are not true beans. A few coffee cherries, referred to as "peaberries" contain a single seed; they make up around 10% to 15% of all coffee beans. It is often claimed that peaberries are superior to normal beans, but there is little hard evidence to support this. Like Brazil nuts (a seed) and white rice, coffee beans consist mostly of endosperm. The two most economically important varieties of coffee plants are the arabica and the robusta, accounting for approximately 60% and 40% of the coffee produced worldwide, respectively. Arabica beans contain 0.8–1.4% caffeine and robusta beans contain 1.7–4.0% caffeine. As coffee is one of the world's most widely consumed beverages, coffee beans are a major cash crop and an important export product, accounting for over 50% of some developing nations' foreign exchange earnings. In 2023 the largest producer of coffee and coffee beans was Brazil. Other main exporters of coffee beans are Colombia, Vietnam, and Ethiopia.
Sources: en.wikipedia.org
A group or series of case reports involving patients who were given similar treatment. Reports of case series usually contain detailed information about the individual patients. This includes demographic information (for example, age, gender, ethnic origin) and information on diagnosis, treatment, response to treatment, and follow-up after treatment. (NCI) Case-control study
Soybeans suffer from the fungus Pythium spinosum in Arkansas and Indiana (United States), and China. In Japan and the United States, the Soybean dwarf virus (SbDV) causes a disease in soybeans and is transmitted by aphids.
In August 2022, Lee and Lifeson returned to the stage at the South Park 25th anniversary concert at Red Rocks Amphitheatre, with South Park's co-creator Matt Stone on drums to perform "Closer to the Heart" alongside the members of Primus; this was their first performance since the death of Peart. In September 2022, Lee and Lifeson performed at the London Taylor Hawkins tribute concert with Dave Grohl and Omar Hakim on drums. They performed "2112: Overture", "Working Man", and "YYZ", the latter of which was Hawkins' favourite Rush song. Later in September 2022, Lee and Lifeson played the same set at the second Taylor Hawkins Tribute show in Los Angeles. Grohl was the drummer again on "2112", Chad Smith of the Red Hot Chili Peppers joined them for "Working Man", and Danny Carey from Tool played drums for "YYZ". Those appearances fuelled speculation over a possible Rush reunion, with Paul McCartney (who attended the Hawkins tribute shows) urging Lee and Lifeson to tour again, and Smith commenting, "Those guys are so happy to be playing again... They were part of the show. They loved it and enjoyed the hell out of it. Those guys miss playing.
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.